Louisiana 2019 Regular Session

Louisiana House Bill HB433

Introduced
3/29/19  
Introduced
3/29/19  
Refer
3/29/19  
Refer
3/29/19  
Refer
4/8/19  
Refer
4/8/19  
Report Pass
5/7/19  
Report Pass
5/7/19  
Engrossed
5/21/19  
Engrossed
5/21/19  
Refer
5/22/19  
Refer
5/22/19  
Report Pass
5/29/19  
Report Pass
5/29/19  
Enrolled
6/3/19  
Enrolled
6/3/19  
Chaptered
6/6/19  
Chaptered
6/6/19  

Caption

Authorizes a pharmacist to decline to dispense a covered prescription drug if the coverage provider reimburses the pharmacy in an amount less than the drug's acquisition cost

Impact

The bill modifies Louisiana state law regarding pharmacies by emphasizing fair reimbursement from pharmacy benefit managers (PBMs). By mandating that pharmacies cannot be compensated less than the amount provided to affiliated PBMs for the same services, this legislation aims to ensure that community pharmacies can sustain their operations morally and economically. The implications extend to protecting pharmacists from retaliation or breach of contract claims if they opt to reject a service that is not financially viable.

Summary

House Bill 433 focuses on the operations and business practices related to pharmacies and pharmacy benefit managers in Louisiana. The bill allows pharmacists to decline providing covered drugs or services if the reimbursement rate from pharmacists is lower than the acquisition cost of the drugs or services. This is a critical change meant to protect pharmacists from being forced to operate at a loss when providing necessary medications or services to their customers, reinforcing their ability to make informed financial decisions while serving their clientele.

Sentiment

Discussions surrounding HB 433 appear to be largely positive among supporters, including many pharmacists and legislators who argue that it empowers small pharmacies and enhances consumer protection. The sentiment reflects a favorable view towards creating a balanced and equitable market for pharmaceuticals. However, concerns about adherence to regulatory frameworks and the potential ramifications for pharmacy benefit managers paint a more cautious narrative among critics who may fear increased operational costs.

Contention

Notable points of contention stem from the interactions between PBMs and pharmacies. While supporters contend that this bill fortifies the position of local pharmacies against potentially predatory practices by larger PBMs, opponents raise questions about how this could lead to an increase in prescription costs or limit the availability of certain drugs. The balance between ensuring fair business practices and maintaining a healthy competitive environment in the pharmacy sector remains a debated aspect of the bill.

Companion Bills

No companion bills found.

Similar Bills

TX HB1763

Relating to the contractual relationship between a pharmacist or pharmacy and a health benefit plan issuer or pharmacy benefit manager.

TX HB1670

Relating to the contractual relationship between a pharmacist or pharmacy and a health benefit plan issuer or pharmacy benefit manager.

TX SB528

Relating to the contractual relationship between a pharmacist or pharmacy and a health benefit plan issuer or pharmacy benefit manager.

TX HB2817

Relating to the contractual relationship between a pharmacist or pharmacy and a health benefit plan issuer or pharmacy benefit manager.

WI AB173

Regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)

WI SB203

Regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)

TX SB2261

Relating to the practices and operation of pharmacy benefit managers; providing administrative penalties.

TX HB2231

Relating to the practices and operation of pharmacy benefit managers; providing administrative penalties.